Morphiex Biotherapeutics

Morphiex biotherapeutics email format

Verified email-pattern data for Morphiex Biotherapeutics is currently limited. You can still use the company insights and contact sections below.
Morphiex is harnessing the power of the immune system to fight cancer by developing the only dual-functioning #CD47 immune checkpoint inhibitor. Our lead drug candidate, MBT-001, blocks both "don't eat me" and thrombospondin-1 (TSP-1) pathways of #CD47. This enables direct tumor cell killing mediated by T cells, Natural Killer cells, Neutrophils as well as Macrophages. MBT-001 was developed at the National Cancer Institute (NCI) at the National Institutes of Health (NIH) and is exclusively licensed to Morphiex for the treatment of cancer as a monotherapy or in combination with other modalities such as chemotherapy, immune checkpoint inhibitors, CAR-T and many others. Morphiex has entered into a cooperative research and development agreement (CRADA) with the NIH/NCI to accelerate the development of MBT-001.

Company Details

Founded
-
Address
240 Newbury Street, 2nd Floor, Boston,massachusetts 02116,united States
Industry
Biotechnology Research
HQ
Boston, Massachusetts
Looking for a particular Morphiex Biotherapeutics employee's phone or email?

Morphiex Biotherapeutics Questions

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant